- Home
- MCRB vs HGBL Comparison
MCRB vs HGBL Comparison
Compare MCRB & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- HGBL
- Stock Information
- Founded
- MCRB 2010
- HGBL 1937
- Country
- MCRB United States
- HGBL United States
- Employees
- MCRB N/A
- HGBL N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- HGBL Business Services
- Sector
- MCRB Health Care
- HGBL Consumer Discretionary
- Exchange
- MCRB Nasdaq
- HGBL Nasdaq
- Market Cap
- MCRB 81.2M
- HGBL 72.3M
- IPO Year
- MCRB 2015
- HGBL N/A
- Fundamental
- Price
- MCRB $7.06
- HGBL $2.05
- Analyst Decision
- MCRB Hold
- HGBL Strong Buy
- Analyst Count
- MCRB 5
- HGBL 1
- Target Price
- MCRB $73.67
- HGBL $4.00
- AVG Volume (30 Days)
- MCRB 146.8K
- HGBL 61.7K
- Earning Date
- MCRB 05-07-2025
- HGBL 05-08-2025
- Dividend Yield
- MCRB N/A
- HGBL N/A
- EPS Growth
- MCRB N/A
- HGBL N/A
- EPS
- MCRB 0.03
- HGBL 0.14
- Revenue
- MCRB N/A
- HGBL $45,361,000.00
- Revenue This Year
- MCRB N/A
- HGBL $10.82
- Revenue Next Year
- MCRB N/A
- HGBL $15.17
- P/E Ratio
- MCRB $213.09
- HGBL $14.79
- Revenue Growth
- MCRB N/A
- HGBL N/A
- 52 Week Low
- MCRB $7.18
- HGBL $1.52
- 52 Week High
- MCRB $30.60
- HGBL $2.74
- Technical
- Relative Strength Index (RSI)
- MCRB 33.07
- HGBL 51.34
- Support Level
- MCRB $8.92
- HGBL $1.96
- Resistance Level
- MCRB $9.97
- HGBL $2.07
- Average True Range (ATR)
- MCRB 1.08
- HGBL 0.08
- MACD
- MCRB -0.06
- HGBL 0.01
- Stochastic Oscillator
- MCRB 10.61
- HGBL 50.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About HGBL Heritage Global Inc.
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.